Indications
Capecitabine is FDA-approved for:

Adjuvant Stage III Dukes'C Colon Cancer - used as first-line monotherapy.
Metastatic colorectal Cancer - used as first-line monotherapy, if appropriate.
Metastatic Breast Cancer - used in combination with docetaxel, after failure of anthracycline-based treatment. Also as monotherapy, if the patient has failed paclitaxel-based treatment, and if anthracycline-based treatment has either failed or cannot be continued for other reasons (ie. the patient has already received the maximum lifetime dose of an anthracycline).

Dose
The usual starting dose is 2,500 mg/m2/day in two divided doses, 12 hours apart. One cycle includes two weeks of treatment followed by one week without treatment. Cycles can be repeated every three weeks.

Dose Adjustments
For mild renal dysfunction (creatinine clearance 30-50 mL/min), it is recommended to reduce dose by 25%.
For severe renal dysfunction (creatinine clearance <30 mL/min), treatment is not recommended.
There is no recommendation for hepatic dysfunction.
For elderly patients, lower doses may be required due to higher incidences of serious adverse reactions.

Side effects
Potential major adverse reactions include:

Cardiovascular: ECG changes, myocardial infarction, angina (these may be more common in patients with pre-existing coronary artery disease)
Dermatological: Hand-foot syndrome (numbness, tingling, pain, redness, or blistering of the palms of the hands and soles of the feet)
Gastrointestinal: diarrhoea (sometimes severe), nausea, stomatitis
Hematological: Neutropaenia, anaemia, thrombocytopaenia
Hepatic: Hyperbilirubinaemia

Drug Interactions
May interact with warfarin and increase bleeding risk.
May inhibit cytochrome CYP2C9 enzyme, and therefore increase levels of substrates such as phenytoin and other substrates of CYP2C9.
Much as fluorouracil, the concomitant use of leucovorin may increase both the efficacy and the toxicity of capecitabine.

Source: wikipedia GFDL

Medic8® Medicines

Page last modified: May 2007